The world's first absorbable heart valve comes out! Xeltis may ignite investor enthusiasm

Dominika Zhurkin, patient of the first feasibility study at Xeltis, underwent a 3-month follow-up examination

Traditional heart valve replacement is affected by many factors outside the surgical procedure. For example, exogenous substances are placed in the body for a long time, which may cause postoperative inflammatory reaction and may face the risk of secondary surgery, which will undoubtedly bring a heavier economic burden and more medical risks to patients.

Swiss Xeltis Medical Devices recently released a good news that it has independently developed the world's first bioabsorbable heart valve. The valve is composed of an absorbable porous matrix biomaterial, which has the function of promoting the growth and natural healing of the body tissue, and the valve is gradually absorbed and digested after the tissue is newly grown. At present, Xeltis has successfully completed the second feasibility study of the heart valve, and the good data has made investors feel at ease.

Xeltis also plans to submit an application for another CE marker for pulmonary valve products to the European Union in 2018 with a view to obtaining the right to promote and sell the product in the EU.

According to Xeltis officially, the company's endogenous tissue repair technology (ETR) is based on the research of supramolecular chemistry by Nobel laureate Professor Jean-Marie Lehn. In essence, the absorbable biological material functions as a heart valve, blood vessel or tissue after being designed and implanted in the body. After the corresponding tissue of the standby body grows and functions, the absorbable biological material can be taken by the body. Absorb or digest on its own.

The company has recently developed a cardio-vascular patch that can be used to correct cardiac malformations in the heart of children with congenital single ventricles. The results of the study showed that all patients had no postoperative complications, and there was no case of surgical intervention due to cardiac dysfunction in one year after surgery.

Although the clinical needs of the repaired valve developed are niche, Xeltis CEO Laurent Grandidier is convinced that the company's efforts will be the cornerstone for the development and development of other cardiovascular membrane-absorbing biomaterials. At present, the company's platform development technology can carry out the development of many cardiovascular replacement valve materials. The advantage of this technology platform has become the biggest highlight attracting investors.

In 2014, private equity firm LSP had raised a huge investment of 27 million euros for Xeltis in the form of a B-series private equity fund. Xeltis's development objective is to achieve steady profit growth with a cost-benefit analysis concept. This business deployment and operation model has always been optimistic for LSP companies and other wealth investors.

At present, Xeltis is actively preparing for the launch of its heart valve products, mainly for the correction of cardiac malformations in children with congenital heart disease, hoping to obtain relevant marketing access permits on time to benefit more patients.